YY1 peptide

  • Check with publisher
  • Published date: February 22, 2019
    • Shirley, New York, United States

YY1 is a ubiquitously distributed transcription factor belonging to the GLI-Kruppel class of zinc finger proteins. The protein is involved in repressing and activating a diverse number of promoters. YY1 may direct histone deacetylases and histone acetyltransferases to a promoter in order to activate or repress the promoter, thus implicating histone modification in the function of YY1. [provided by RefSeq, Jul 2008]
https://www.creative-diagnostics.com/YY1-peptide-178398-427.htm

Thomas Schmitt
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • XBP1 peptide

    XBP1 peptide

    Biomedical Sciences Shirley (New York) February 22, 2019 Check with publisher

    This gene encodes a transcription factor that regulates MHC class II genes by binding to a promoter element referred to as an X box. This gene product is a bZIP protein, which was also identified as a cellular transcription factor that binds to an en...

  • WWOX peptide

    WWOX peptide

    Biomedical Sciences Shirley (New York) February 22, 2019 Check with publisher

    WW domain-containing proteins are found in all eukaryotes and play an important role in the regulation of a wide variety of cellular functions such as protein degradation, transcription, and RNA splicing. This gene encodes a protein which contains 2 ...

  • GM-CSF-Secreting Tumor Cell Vaccines

    GM-CSF-Secreting Tumor Cell Vaccines

    Biomedical Sciences Shirley (New York) January 28, 2019 Check with publisher

    Cytokines have been used to treat advanced cancers, including renal cell carcinoma and melanoma with some success, but systemic administration is associated with marked toxicity. Recombinant cytokines expressed by modified tumor cells can be used to ...